本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 贵阳新天药业股份有限公司（以下简称"公司"）第七届董事会第三十次会 议通知已于2025年4月13日以电子邮件等方式发出，会议于2025年4月23日上午 9:00在上海市徐汇区东安路562号22楼（近龙华中路，绿地缤纷城）以现场结合 通讯表决的方式召开。会议应到董事9名，实际出席会议并表决的董事9名（其中 出席现场会议表决的董事有王光平先生、王文意先生、季维嘉女士、官峰先生、 张捷女士共5人，董事董大伦先生、王金华先生、何忠磊先生、高立金先生共4 人以视频等通讯方式出席会议）。会议由董事长董大伦先生主持，公司监事和高 级管理人员列席会议。本次会议的召开符合《公司法》等法律、行政法规、规范 性文件和《公司章程》的有关规定。 二、董事会会议审议情况 1、审议通过《关于 2024 年度总经理工作报告的议案》 2024 年，公司经营管理层在董事会的带领下，切实履行各项职责，贯彻落 实股东大会、董事会的各项决议，勤勉尽责地开展各项工作，在持续深化市场营 销体系改革、提升公司研发能力、升级品牌营销战略， ...

贵阳新天药业股份有限公司 关于2024年度利润分配预案的公告 证券代码：002873 证券简称：新天药业 公告编号：2025-022 二、2024 年度利润分配预案的基本情况 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 （一）本次利润分配预案的基本内容 特别提示： 1、根据《公司法》有关规定，贵阳新天药业股份有限公司（以下简称"公 司"）已回购的股份不享有利润分配权。本次利润分配预案为：拟以未来实施利 润分配方案时股权登记日的总股本（不含公司回购专户中的股份）为基数，向全 体股东每 10 股派发现金红利人民币 0.60 元（含税），不送红股，不以资本公积 转增股本。 2、公司于 2025 年 4 月 23 日召开的第七届董事会第三十次会议、第七届监 事会第二十一次会议已审议通过了《关于 2024 年度利润分配预案的议案》，该 议案尚需提交公司 2024 年年度股东大会审议。 3、在实施权益分派的股权登记日前公司总股本发生变动的，拟维持每股分 配金额不变的原则，相应调整分配总额，具体分配总额以实际分派金额为准。 一、审议程序 公司于 2025 年 4 月 2 ...

一、主要会计数据和财务指标 | 名称 持有数量(万股) | | 占总股本比 | 增减情况 | | --- | --- | --- | --- | | | | 例(%) | (万股) | | 上海新天智药生物技术有限公司 | 7776.37 | 32.57 | 不变 | | 张全槐 | 997.35 | 4.18 | 不变 | | 上海国盛资本管理有限公司-上海国盛海通股权投资基金 | | | | | 合伙企业(有限合伙) | 242.35 | 1.01 | 不变 | | 贵阳开元生物资源开发有限公司 | 166.97 | 0.70 | 不变 | | 王金华 | 154.93 | 0.65 | -2.82 | | 上海银叶投资有限公司-银叶-攻玉主题精选2期私募证券 投资基金 | 150.85 | 0.63 | 不变 | | 马晟 | 107.50 | 0.45 | 新进 | | 博道远航混合A | 104.91 | 0.44 | 新进 | | 颜之华 | 98.90 | 0.41 | 14.34 | | 蔡强 | 96.23 | 0.40 | 新进 | | 较上个报告期退出前十大股东有 | | | | | 王 ...

Financial Performance - The company's operating revenue for 2024 was ¥857,548,653.35, a decrease of 10.11% compared to ¥953,981,876.69 in 2023[18]. - Net profit attributable to shareholders for 2024 was ¥52,322,877.14, down 35.30% from ¥80,871,062.07 in 2023[18]. - The net profit after deducting non-recurring gains and losses was ¥35,131,052.77, a decline of 53.16% from ¥75,009,549.39 in 2023[18]. - The basic earnings per share for 2024 was ¥0.2375, a decrease of 31.93% compared to ¥0.3489 in 2023[18]. - The total assets at the end of 2024 were ¥1,950,501,320.49, an increase of 2.02% from ¥1,911,798,773.73 at the end of 2023[18]. - The net assets attributable to shareholders increased by 7.31% to ¥1,194,715,847.70 at the end of 2024 from ¥1,113,331,133.10 at the end of 2023[18]. - The net cash flow from operating activities for 2024 was ¥88,130,214.33, an increase of 13.30% from ¥77,782,320.97 in 2023[18]. - The weighted average return on equity for 2024 was 5.02%, down from 7.01% in 2023[18]. Revenue Breakdown - The company's total revenue for the first quarter was ¥177,321,934.57, with a net profit attributable to shareholders of ¥15,571,957.55[22]. - In the second quarter, revenue increased to ¥264,377,493.59, while net profit decreased slightly to ¥14,767,492.94[22]. - The third quarter saw a revenue of ¥219,145,829.65 and a significant increase in net profit to ¥30,660,310.74[22]. - The fourth quarter reported a revenue of ¥196,703,395.54, but a net loss of ¥8,676,884.09 was recorded[22]. - The main business revenue was ¥856,873,728.73, accounting for 99.92% of total revenue, also down by 10.11% year-on-year[68]. - The gynecology product category generated ¥613,469,860.20, which is 71.54% of total revenue, reflecting a decline of 9.21% from the previous year[68]. Research and Development - The company has established a comprehensive R&D platform covering the entire lifecycle of drug development, including new drug discovery, quality standards research, and clinical evaluation[34]. - The company is focusing on the development of innovative traditional Chinese medicine (TCM) drugs, particularly in gynecology and urology, with a robust pipeline of 1.1 class innovative drugs[62]. - The innovative drug pipeline includes treatments for bacterial vaginosis and chronic prostatitis, with ongoing projects aimed at prostate hyperplasia and related inflammation[62][63]. - The company has 29 invention patents, 2 utility model patents, and 13 design patents, demonstrating a strong focus on innovation in traditional Chinese medicine[46]. - The company is actively developing over 300 traditional Chinese medicine formula granules, covering areas such as gynecology, pediatrics, and geriatrics[46]. - The company emphasizes a "production-generation, reserve-generation, development-generation" strategy for research and development in traditional Chinese medicine[45]. Market Strategy and Positioning - The company aims to enhance its market presence in women's health, urology, and chronic diseases, while also expanding into elderly and pediatric medications[35]. - The flagship product, He Yan® Kun Tai Capsule, ranks first in both hospital and retail sectors for menopausal traditional Chinese medicine in 2023, indicating strong market performance[41]. - The product Ning Pi Tai® Ning Pi Tai Capsule ranks fifth in the hospital sector for urinary tract infection traditional Chinese medicine in 2023, showcasing its competitive position[42]. - The product Ku Li Shu® Ku Shen Gel ranks third in the hospital sector for gynecological inflammation external use traditional Chinese medicine in 2023, reflecting its effectiveness and market acceptance[43]. - The company aims to become a leading brand in its niche market within the next 3-5 years, focusing on the strategy of "big single product + strong brand"[54]. - The marketing model emphasizes professional market promotion, which has improved product recognition and trust among clinical doctors and patients[52]. Operational Efficiency - The company has completed the automation and intelligent upgrades of multiple production lines, establishing a smart capacity supply guarantee center, which will significantly enhance production efficiency and cost control[51]. - The company has implemented a centralized procurement system to manage inventory and ensure the availability of necessary materials for production[48]. - The company has received 11 national new drug certificates and 31 drug approval numbers, indicating a robust pipeline of products[46]. - The company adheres to GMP standards in its production processes, ensuring high-quality manufacturing[49]. - The company has initiated a reform of its marketing system since 2022, focusing on cost reduction and efficiency improvement, which has led to a decrease in sales expense ratio[68]. Risk Management - The management discussed potential risks and countermeasures in the future development outlook section of the report[3]. - The company faces industry policy risks, including potential price declines due to healthcare reforms, and plans to mitigate this by expanding sales channels and enhancing product quality[106]. - The company acknowledges product development risks, including long cycles and high costs, and is focused on project management and protecting core technologies[107]. - The company is addressing accounts receivable risks by strengthening management and monitoring processes to ensure timely collections[107]. - Environmental risks are acknowledged due to production processes, and the company is committed to maintaining compliance with regulations while managing costs[108]. Corporate Governance - The board of directors consists of 9 members, including 3 non-independent directors, complying with legal and regulatory requirements[115]. - The supervisory board remains unchanged with 3 members, including 1 employee representative, fulfilling its supervisory role effectively[116]. - The company has established a complete business system and operates independently from its controlling shareholder, ensuring no competition with related parties[114]. - The company has a remuneration decision-making process involving the shareholders' meeting and the board of directors, with a dedicated compensation and assessment committee[145]. - The company has established an internal control system to ensure compliance and effective operation[121]. Shareholder Engagement - The company emphasizes shareholder returns through dividends and active investor relations management, aiming to enhance its investment value[105]. - The company plans to distribute a cash dividend of ¥0.60 per 10 shares to shareholders[3]. - The annual shareholders' meeting had a participation rate of 42.90% on May 13, 2024[129]. - The first temporary shareholders' meeting in 2024 had a participation rate of 37.89% on September 20, 2024[129]. - The second temporary shareholders' meeting in 2024 had a participation rate of 35.11% on December 23, 2024[129]. Environmental Responsibility - The company adheres to national and local environmental protection laws and regulations in its operations[175]. - The company has successfully implemented environmental protection measures, with all facilities operating continuously and meeting discharge standards[180]. - The company has received environmental protection administrative approvals for its projects, ensuring compliance with industry standards[179]. - The company has established emergency response plans for environmental incidents, with annual training and drills conducted[185]. - The company has a comprehensive waste management strategy, including the proper disposal of hazardous waste according to environmental regulations[184].

Financial Performance - The company's revenue for Q1 2025 was CNY 193,151,214.98, representing an increase of 8.93% compared to CNY 177,321,934.57 in the same period last year[5]. - Net profit attributable to shareholders decreased by 73.11% to CNY 4,187,454.45 from CNY 15,571,957.55 year-on-year[5]. - The net profit after deducting non-recurring gains and losses fell by 81.21% to CNY 2,765,376.35 compared to CNY 14,715,210.15 in the previous year[5]. - Basic earnings per share dropped by 74.44% to CNY 0.0172 from CNY 0.0673 in the same period last year[5]. - Total operating revenue for the current period reached ¥193,151,214.98, an increase of 8.3% compared to ¥177,321,934.57 in the previous period[17]. - Net profit for the current period was ¥4,187,454.45, a decrease of 73.1% compared to ¥15,571,957.55 in the previous period[18]. - Basic earnings per share decreased to ¥0.0172 from ¥0.0673, reflecting a significant decline in profitability[18]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 22.43% to CNY 15,986,135.81 from CNY 20,608,457.90 year-on-year[5]. - Cash flow from operating activities generated a net amount of ¥15,986,135.81, down 22.5% from ¥20,608,457.90 in the previous period[20]. - The company reported a net cash outflow from financing activities of CNY -22,937,787.36, a significant increase in outflow compared to CNY -4,751,467.96 in the previous year[9]. - The company experienced a net cash outflow from financing activities of ¥22,937,787.36, worsening from an outflow of ¥4,751,467.96 in the previous period[22]. - The company's cash and cash equivalents decreased from CNY 118,164,427.88 to CNY 99,758,021.83, a decline of approximately 15.5%[14]. - Cash and cash equivalents at the end of the period totaled ¥99,758,021.83, a decrease from ¥140,605,931.76 at the end of the previous period[22]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,917,497,598.80, a decrease of 1.69% from CNY 1,950,501,320.49 at the end of the previous year[5]. - Total current assets decreased from CNY 616,807,046.83 to CNY 588,809,486.84, a decline of about 4.5%[14]. - Total liabilities decreased from CNY 755,785,472.79 to CNY 718,594,296.65, a reduction of approximately 4.9%[16]. - The total assets decreased from CNY 1,950,501,320.49 to CNY 1,917,497,598.80, a decline of approximately 1.7%[14]. - The company's retained earnings increased from CNY 563,396,301.30 to CNY 567,583,755.75, reflecting a growth of about 0.4%[16]. - The total equity attributable to the parent company increased slightly from CNY 1,194,715,847.70 to CNY 1,198,903,302.15, an increase of approximately 0.3%[16]. Borrowings and Financing - Short-term borrowings decreased by 60.44% to CNY 121,134,180.55 from CNY 306,242,291.69, reflecting a repayment of bank loans[9]. - Long-term borrowings increased significantly from CNY 221,400,000.00 to CNY 391,880,000.00, an increase of about 77%[16]. - The company's short-term borrowings decreased significantly from CNY 306,242,291.69 to CNY 121,134,180.55, a reduction of about 60.5%[16]. Research and Development - Research and development expenses increased by 74.89% to CNY 9,153,093.49 from CNY 5,233,578.17 year-on-year, indicating a significant investment in innovation[9]. - Research and development expenses increased to ¥9,153,093.49, up 74.5% from ¥5,233,578.17, indicating a focus on innovation[17]. Inventory and Receivables - Accounts receivable increased from CNY 308,443,933.77 to CNY 319,507,090.39, reflecting a growth of about 3.4%[14]. - Inventory decreased from CNY 145,478,159.62 to CNY 129,515,012.25, a reduction of approximately 11%[14]. - Sales expenses rose to ¥84,366,283.27, an increase of 9.6% compared to ¥77,379,857.99 in the previous period[17].

贵阳新天药业股份有限公司 证券代码：002873 证券简称：新天药业 公告编号：2025-014 近日，贵阳新天药业股份有限公司收到全资子公司上海硕方医药科技有限公 司通知，其经营范围增加了"地产中草药（不含中药饮片）购销"项目，已完 成工商变更登记手续，并取得上海市奉贤区市场监督管理局换发的《营业执照》， 具体情况如下： 一、新取得《营业执照》的基本信息 统一社会信用代码：91310115MA1K45061F 名称：上海硕方医药科技有限公司 关于全资子公司变更经营范围并取得营业执照 的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 类型：有限责任公司（非自然人投资或控股的法人独资） 法定代表人：董大伦 注册资本：人民币 3000.0000 万元整 2 1、上海硕方医药科技有限公司登记通知书； 2、上海硕方医药科技有限公司营业执照。 特此公告。 贵阳新天药业股份有限公司 董事会 2025 年 4 月 18 日 成立日期：2018 年 07 月 15 日 住所：上海市奉贤区望园路 1888 号 1 幢 5 层 经营范围：一般项目：技术服务、技术开发、技术咨 ...

证券代码：002873 证券简称：新天药业 公告编号：2025-015 贵阳新天药业股份有限公司 关于举行2024年度业绩网上说明会的公告 本次年度业绩说明会将采用网络远程的方式举行，投资者可通过访问 https://eseb.cn/1nwgQWULvfq 或微信扫描以下二维码参与本次年度业绩说明会。 出席本次年度业绩说明会的人员有：公司董事长、总经理董大伦先生；董事、 1 会议召开时间：2025 年 4 月 28 日（星期一）15:00-16:30 会议召开方式：网络文字互动方式 会议召开地点：价值在线（www.ir-online.cn） 副总经理、董事会秘书王光平先生；财务总监曾志辉女士；独立董事官峰先生。 为提升投资者交流的针对性，公司就 2024 年度业绩网上说明会提前向投资 者 公 开 征 集 问 题 。 投资者可于 2025 年 4 月 28 日前访问网址 https://eseb.cn/1nwgQWULvfq 或使用微信扫描上方小程序码进行会前提问，公司 将通过本次业绩说明会，在信息披露允许范围内就投资者普遍关注的问题进行回 答。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 ...

证券代码：002873 证券简称：新天药业 公告编号：2025-013 贵阳新天药业股份有限公司 关于控股股东部分股份质押展期的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 贵阳新天药业股份有限公司（以下简称"公司"或"上市公司"）近日收到 控股股东上海新天智药生物技术有限公司（以下简称"新天智药"）的通知，新 天智药对其持有的公司部分股份办理了质押展期业务，具体情况如下： | | 是否控 | | 占其所 | 占公 | 是 否 | 是否 | 质押 | 原质 | 展期 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 股东 | 股股东 | 本次质押 | 持股份 | 司总 | 为 | 为补 | 起始 | 押到 | 后到 | 质权人 | 质押 | | 名称 | 及一致 | 数量（股） | | 股本 | 限 | 充质 | | | | | 用途 | | | 行动人 | | 比例 | 比例 | 售 | 押 | 日 | 期日 | 期日 | | | | | ...

证券代码：002873 证券简称：新天药业 公告编号：2025-012 | 外科仪器和器械；医疗器械和仪 | 器；按摩器械（医用）；牙科设 | 年 | 月 | 日 | 2025 | 03 | 07 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 国际分 | 通长乐 | 第 | 号 | 备和仪器；医用电热垫；避孕套； | 至 | 5 | 80787105 | 类：10 | | 非包扎用弹性绷带；缝合材料； | 年 | 月 | 日 | 2035 | 03 | 06 | 医用冷敷贴 | | | 咖啡用调味品；茶；糖；谷类制 | 品；以谷物为主的零食小吃；食 | 年 | 月 | 日 | 2025 | 03 | 07 | | | 国际分 | 通长乐 | 第 | 号 | 品用香料（含醚香料和香精油除 | 至 | 6 | 80794583 | 类：30 | | 外）；冰淇淋；蜂蜜；食用预制 | 年 | 月 | 日 | 2035 | 03 | 06 | 谷蛋白 | | | 啤酒；果汁；水（饮料）；制无 | 酒精饮料用配料；无酒精饮料； | 年 | 月 ...

证券代码：002873 证券简称：新天药业 公告编号：2025-011 1、公司本次《药品生产许可证》变更的内容主要是删除了"贵州省贵阳市 贵阳国家高新技术产业开发区新添大道114号：中药提取车间***"的生产地址。 2、变更后的《药品生产许可证》内容如下： 贵阳新天药业股份有限公司 关于药品生产许可证变更的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 贵阳新天药业股份有限公司（以下简称"公司"）因中药提取产线搬迁向贵 州省药品监督管理局（以下简称"贵州药监局"）申请变更《药品生产许可证》， 该事项已获批准并于近日取得了贵州药监局换发的《药品生产许可证》。现将有 关情况公告如下： 一、公司变更后的《药品生产许可证》基本情况 企业名称：贵阳新天药业股份有限公司 许可证编号：黔20160010 社会信用代码：91520115214595556N 分类码：AhzyCh 注册地址：贵州省贵阳市贵阳国家高新技术产业开发区新添大道114号 日常监督管理机构：贵州省药品监督管理局 法定代表人：董大伦 企业负责人：董大伦 质量负责人：何容 1 生产地址和生产范围： 以 ...